Cas No.: | 330789-03-2 |
Chemical Name: | N-[4-[4-Amino-1-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide |
Synonyms: | N-[4-[4-Amino-1-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide;A-420983 |
SMILES: | NC1N=CN=C2N(C3CCC(N4CCN(C)CC4)CC3)N=C(C3C=CC(NC(C4=CC5C(=CC=CC=5)N4C)=O)=C(OC)C=3)C=12 |
Formula: | C33H39N9O2 |
M.Wt: | 593.72186 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | A-420983 is a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. |
In Vitro: | DS-70 (α4 integrin inhibitor DS-70) is a novel potent α/β- peptidomimetic antagonist of α4 integrin, binds to integrin α4β1 with nanomolar affinity; prevents the adhesion of α4 integrin-expressing cells, antagonizes VCAM-1-mediated degranulation of mast cells and eosinophils and ERK 1/2 phosphorylation; does not inhibit cell adhesion mediated by the leukocyte integrins aLb2 and aMb2 or by the Arg-GlyAsp (RGD)-binding integrins α5β1, αVβ3, αVβ5, αVβ6 and αIIbβ3; dose-dependently reduces the clinical symptoms of allergic conjunctivitis, conjunctival α4 integrin expression and conjunctival levels of chemokines and cytokines in ovalbumin-sensitized guinea pigs |